J&J's First-Quarter Profit Exceeds Estimates, While Stelara Sales Disappoint

While the earnings beat is a positive development, disappointing sales of the key drug Stelara send mixed signals. Technical indicators present a neutral outlook; the price is near the SMA20 and SMA50 averages, the RSI is in neutral territory, and the MACD shows a weak negative signal. In the short term, a strong directional move is not expected as positive earnings and negative sales news balance each other out and technicals remain neutral. The market will focus on the details of the news and management guidance.